The Therapeutic Effects of Intralesional Injection of Nimodipine on the Treatment of Resistant Cases of Cutaneous Leishmaniasis

Document Type : Original Article (s)

Authors

1 Professor, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Associate Professor, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Assistant Professor, Clinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran

4 Assistant Professor, Department of Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

5 Dermatologist, Mashhad University of Medical Sciences, Mashhad, Iran

6 Resident, Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: In this study, we evaluated the efficacy of intralesional injection of nimodipine in treatment of some cases of cutaneous leishmaniasis failed by a course of intralesional meglumine antimoniate (Glucantime).Methods: This semi-experimental clinical trial study was done at the leishmaniasis research center of Mashhad University of Medical Sciences, Mashhad, Iran, from 2017 to 2018. For the patients whom their treatment had failed after a complete course of intralesional injection of meglumine antimoniate, intralesional injection of nimodipine was administered once a week for 6 weeks.Findings: Ten patients were assessed. The mean size of the lesions were 1.35 cm at the first day of treatment, and became subsequently 1.35, 1.35, 1.33, 1.33, and 1.32 cm at the end of 2nd to 6th weeks of the treatment. Moreover, one month after the end of the treatment, the mean size of the lesions was 1.32 cm. The induration change of lesions was less than 25% for eight patients, and 25-50 percent for two other patients, after the fourth week; these changes were not statistically significant.Conclusion: There was no significant difference in size and induration of the lesions one month after the treatment with nimodipine compared to the first session of treatment. The concentration of the drug, or the selection of specific patients, may affect the results. This should be considered in the future studies.

Keywords

References

  1. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103(1): 33-40.
  2. Yazdanpanah MJ, Mostofi K, Soleimani M, Ebrahimirad M. Oral administration of zinc sulphate in treatment of acute cutaneous leishmaniasis. Iran Red Crescent Med J 2007; 9(4): 205-8.
  3. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis 2010; 2(2): 167-76.
  4. Reimao JQ, Scotti MT, Tempone AG. Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study. Bioorg Med Chem 2010; 18(22): 8044-53.
  5. Reimao JQ, Tempone AG. Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs. Mem Inst Oswaldo Cruz 2011; 106(8): 1032-8.
  6. Shokri A, Sharifi I, Khamesipour A, Nakhaee N, Fasihi HM, Nosratabadi J, et al. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res 2012; 110(3): 1113-7.
  7. Reimao JQ, Mesquita JT, Ferreira DD, Tempone AG. Investigation of calcium channel blockers as antiprotozoal agents and their interference in the metabolism of Leishmania (L.) infantum. Evid Based Complement Alternat Med 2016; 2016: 1523691.
  8. Tempone AG, Taniwaki NN, Reimao JQ. Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine. Parasitol Res 2009; 105(2): 499-505.
  9. Neal RA, van Bueren J, McCoy NG, Iwobi M. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 1989; 83(2): 197-8.
Journal of Isfahan Medical School
Volume 37, Issue 544 - Serial Number 544
July and August 2019
Pages 1112-1116

Files

History

  • Receive Date: 12 September 2019
  • Revise Date: 25 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics